{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-25-000042","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2025-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.418115+00:00","generated_at":"2026-05-23T15:32:47.112245+00:00","sec_items":["1.01","3.02","3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Serina Therapeutics raises $5M via convertible preferred stock for Parkinson's drug SER-252","bullets":["Issued 962,250 shares of Series A Convertible Preferred at $5.18/share for ~$5M gross proceeds.","Preferred stock carries 8% cumulative annual dividend, paid in kind; convertible at $5.18 per common share.","Proceeds to support SER-252 (POZ-apomorphine) Phase 1 trial initiation in Q4 2025 for advanced Parkinson's.","Financing from strategic shareholders; conversion triggers include stock price doubling or $20M+ equity raise."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-25-000042","json":"https://secwatch.observer/filing/0001708599-25-000042.json","markdown":"https://secwatch.observer/filing/0001708599-25-000042.md","text":"https://secwatch.observer/filing/0001708599-25-000042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/0001708599-25-000042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/ser-20250408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T15:32:47.112245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6d7dd52232de2b7c1dcd609e2821b556bb31c2d","claim":"Serina Therapeutics, Inc.: Filed Certificate of Designations for Series A Convertible Preferred Stock, establishing rights, preferences, and limitations (effective 2025-04-10).","evidence_excerpt":"On April 10, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the \"Certificate of Designations\") with the Secretary of State of the State of Delaware, which became effective upon filing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/0001708599-25-000042-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-04-10"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}